| Name | Title | Contact Details |
|---|---|---|
Bob Smith |
Chief Commercial Officer | Profile |
Danielle Wiener |
Associate Director, Clinical Supply Chain | Profile |
Mario Orlando |
VP, Commercial New Product Planning | Profile |
Annie Enriquez |
Associate Director, Human Resources and Talent Acquisition | Profile |
Faheem Hasnain |
Chairman and Chief Executive Officer | Profile |
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.